Rsf-1 expression in rectal cancer: With special emphasis on the independent prognostic value after neoadjuvant chemoradiation

Journal of Clinical Pathology

Volumn 65, Issue 8, 2012, Pages 687-692

  Lin, Ching Yih ^a,b   Tian, Yu Feng ^a,c   Wu, Li Ching ^a   Chen, Li Tzong ^d   Lin, Li Ching ^a   Hsing, Chung Hsi ^a   Lee, Sung Wei ^a   Sheu, Ming Jen ^a   Lee, Hao Hsien ^a   Wang, Yu Hui ^e   Shiue, Yow Ling ^f   Wu, Wen Ren ^f   Huang, Hsuan Ying ^g   Hsu, Han Ping ^h   Li, Chien Feng ^a,d,f,i,j   Chen, Shang Hung ^a,d,e  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^g CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

ⁱ SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^j CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR PROTEIN; PROTEIN RSF 1; UNCLASSIFIED DRUG;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR BIOPSY;

ADENOCARCINOMA; AGED; BIOPSY; CHEMORADIOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAIWAN; TIME FACTORS; TRANS-ACTIVATORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84864557910     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200786     Document Type: Article

References (30)

1. Bosset JF, Calais G, Mineur L, et al. Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results of EORTC 22921. J Clin Oncol 2005;23:5620-7.
2. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fl uorouracil and leucovorin in T3-T4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-5. (Pubitemid 46630960)
3. Bosset JF, Collette L, Calais G, et al. Chemotherapy with pre-operative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23. (Pubitemid 44394918)
4. Read TE, McNevin MS, Gross EK, et al. Neoadjuvant therapy for adenocarcinoma of the rectum: tumor response and acute toxicity. Dis Colon Rectum 2001;44:513-22. (Pubitemid 32336425)
5. Hyams DM, Mamounas EP, Petrelli N, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Adjuvant Breast and Bowel Project protocol R-03. Dis Colon Rectum 1997;40:131-9. (Pubitemid 27074280)
6. Valentini V, Coco C, Cellini N, et al. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys 1998;40:1067-75. (Pubitemid 28152921)
7. Wagman R, Minsky BD, Cohen AM, et al. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 1998;42:51-7. (Pubitemid 28435595)
8. Loyola A, Huang JY, LeRoy G, et al. Functional analysis of the subunits of the chromatin assembly factor RSF. Mol Cell Biol 2003;23:6759-68. (Pubitemid 37214647)
9. Sheu JJ, Choi JH, Yildiz I, et al. The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. Cancer Res 2008;68:4050-7.
10. Shih IM, Sheu JJ, Santillan A, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A 2005;102:14004-9. (Pubitemid 41377693)
11. Davidson B, Trope CG, Wang TL, et al. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol 2006;103:814-19. (Pubitemid 44821313)
12. Schwab M. Amplification of oncogenes in human cancer cells. Bioessays 1998;20:473-9. (Pubitemid 28320609)
13. Chen TJ, Huang SC, Huang HY, et al. Rsf-1/HBXAP overexpression is associated with disease-specific survival of patients with gallbladder carcinoma. APMIS 2011;119:808-14.
14. Tai HC, Huang HY, Lee SW, et al. Associations of Rsf-1 overexpression with poor therapeutic response and worse survival in patients with nasopharyngeal carcinoma. J Clin Pathol 2012;65:248-53.
15. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th edn. New York, NY: Springer, 2010:16.
16. Dworak O, Keiholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997;12:19-23. (Pubitemid 27138353)
17. Ho L, Crabtree GR. Chromatin remodelling during development. Nature 2010;463:474-84.
18. Wolffe AP. Chromatin remodeling: why it is important in cancer. Oncogene 2001;20:2988-90. (Pubitemid 32553552)
19. Lafon-Hughes L, Di Tomaso MV, Méndez-Acuña L, et al. Chromatin-remodelling mechanisms in cancer. Mutat Res 2008;658:191-214.
20. Choi JH, Sheu J, Guan B, et al. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res 2009;69:1407-15.
21. Sheu JJ, Guan B, Choi JH, et al. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem 2010;285:38260-9.
22. Shamay M, Barak O, Shaul Y. HBXAP, a novel PHD-finger protein, possesses transcription repression activity. Genomics 2002;79:523-9. (Pubitemid 34274293)
23. Fang FM, Li CF, Huang HY, et al. Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, Correlates with aggressive oral squamous cell carcinoma. Am J Pathol 2011;178:2407-15.
24. Janjan NA, Khoo VS, Abbruzzese J, et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999;44:1027-38. (Pubitemid 29342903)
25. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
26. Giralt J, de las Heras M, Cerezo L, et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 2005;74:101-8. (Pubitemid 40331866)
27. Fernebro E, Bendahl PO, Dictor M, et al. Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. Int J Cancer 2004;111:921-8. (Pubitemid 39096241)
28. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-96. (Pubitemid 46211512)
29. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60. 30.
30. Facchino S, Abdouh M, Chatoo W, et al. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci 2010;30:10096-111.